Symbols

PCRX

Pacira BioSciences·NASDAQ

--(--)

PCRX fundamentals

PCRX Q4 2025 Earnings

Pacira BioSciences (PCRX) released its earnings on Feb 26, 2026: revenue was 196.87M (YoY +5.14%), missed estimates; EPS was 0.57 (YoY -37.36%), missed estimates.

Revenue / YoY

196.87M

+5.14%

EPS / YoY

0.57

-37.36%

Report date

Feb 26, 2026

PCRX Earnings Call Summary for Q4,2025

Revenue Growth: 2025 revenue up 15% to $72 million, with EXPAREL volumes +7% in Q4. On track for 3 million+ patients/year by 2030.
Exclusivity & IP: EXPAREL protected through 2039 with 21 patents, enabling steady growth.
Pipeline Momentum: PCRX-201 Phase II ASCEND study to report safety and efficacy trends in late 2026; LG Chem partnership to launch EXPAREL in APAC in 2027.
Financial Strength: 80% gross margin in Q4 2025, $238 million cash, and $150 million share buyback program.
Partnerships: J&J MedTech to drive ZILRETTA growth; LG Chem to expand EXPAREL into APAC markets.

Earnings

EPS

Revenue

Revenue & Expenses

PCRX has released its 2025 Q4 earnings report, with revenue of 196.87M, reflecting a YoY change of 5.14%, and net profit of 1.64M, showing a YoY change of -89.79%. The Sankey diagram below clearly presents PCRX's revenue sources and cost distribution.

Key Indicators

Pacira BioSciences (PCRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Pacira BioSciences (PCRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Pacira BioSciences (PCRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Pacira BioSciences (PCRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown